Ana Amb, in Burlington, CO - Occupational Therapist

Ana Amb, is a Occupational Therapist based in Burlington, Colorado. Ana Amb is licensed to practice in * (Not Available) (license number ) and her current practice location is 942 Rose Ave, Burlington, Colorado. She can be reached at her office (for appointments etc.) via phone at (719) 346-6050.

NPI number for Ana Amb is 1376009217 and her current mailing address is 942 Rose Ave, Burlington, Colorado. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1376009217.

Contact Information

	Ana Amb,
	942 Rose Ave, Burlington, CO 80807-1815
	(719) 346-6050
	Not Available

Healthcare Provider's Profile

Full Name	Ana Amb
Gender	Female
Speciality	Occupational Therapist
Location	942 Rose Ave, Burlington, Colorado
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1376009217
Provider Enumeration Date: 02/15/2019
Last Update Date: 02/15/2019

Medical Identifiers

Medical identifiers for Ana Amb such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1376009217	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ana Amb is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ana Amb, 942 Rose Ave, Burlington, CO 80807-1815 Ph: (719) 346-6050	Ana Amb, 942 Rose Ave, Burlington, CO 80807-1815 Ph: (719) 346-6050

News Archive

Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study

Results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease were published this week in the Journal of the American Society of Nephrology. The published study results suggest that atrasentan, used in conjunction with renin-angiotensin system inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes.

Newborns of mothers who smoke during pregnancy have altered stress hormones, DNA

Researchers from The Miriam Hospital have studied the effects of smoking during pregnancy and its impact on the stress response in newborn babies. Their research indicates that newborns of mothers who smoke cigarettes during pregnancy show lower levels of stress hormones, lowered stress response, and alterations in DNA for a gene that regulates passage of stress hormones from mother to fetus.

WHO's goal to provide life-long antiretroviral therapy to 3 million people with HIV/AIDS at risk of failing

Lack of financial resources, staff, and commitment from key countries, may hamper WHO's goal to provide life-long antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005 (3 by 5), states an editorial in this week's issue of The Lancet.

Survey: 91% of people around the world believe medical research will result in dementia cure

A new survey from Novartis, Amgen and Banner Alzheimer's Institute, along with Alzheimer's Disease International, shows that 91% of people from around the world believe medical research will result in a treatment for dementia.

Ana Amb, - Occupational Therapist in Burlington, CO